Clinical Trials: From the Editor
1-20 of 36 Next
From the Desk of Evan Yu: “The CARD trial creates a new standard…for certain patients.”
At the European Society of Medical Oncology (ESMO) Congress 2019, the randomized phase 3 CARD trial was presented, with a simultaneous publication in the New England Journal of Medicine.1 This trial randomized 255 men with metastatic castration-resistant prostate cancer in a 1:1 fashion, who previously received docetaxel and an Androgen-Signaling-targeted Inhibitor (ASI), either abiraterone or enzalutamide, to cabazitaxel 25 mg/m2 plus prednisone and granulocyte colony-stimulating factor or the other ASI.
From the Desk of Evan Yu: "What Works for Breast Cancer Should Work for Prostate Cancer, Right?"
From the Desk of Evan Yu: “Is HER2 Still a Worthwhile Therapeutic Target for Urothelial Bladder Cancer?”
From the Desk of Evan Yu: “Polycomb Complex Enhancer of Zeste 2 (EZH2), A Regulator of Lineage Reprogramming and A New Drug Target.”
From the Desk of Evan Yu: “Heating Things Up in a Volatile Marriage…Bispecific Antibody Therapy in Prostate Cancer.”
From the Desk of Evan Yu: "Enzalutamide and Apalutamide Now Offer Survival Benefit for Patients with Metastatic Castration-sensitive Prostate Cancer, but How Do Things Change Now and What Should We Be Doing Next?"
From the Desk of Evan Yu: “Androgen Receptor Mutations in Prostate Cancer; A Worthwhile Therapeutic Target?”
From the Desk of Evan Yu: “The Next Step in Bladder Cancer Immune-Oncology Therapy? Combination Therapy!”
From the Desk of Evan Yu: “Fluciclovine (Axumin®) PET/CT Imaging in Prostate Cancer: More Uses than Just for Recurrent Disease?”
From the Desk of Evan Yu: “PARP with PD-1/PD-L1 inhibition. Is there any magic to the combination in a molecularly unselected patient population?”
From the Desk of Evan Yu: “Is Testosterone Such a Bad Thing for Prostate Cancer? Rationale for Using Supraphysiologic Testosterone to Treat Castration-Resistant Prostate Cancer.”
From the Desk of Evan Yu: “Clinical Trial Updates of Single-Agent PARP Inhibitor Use in Homologous Recombination Deficient Prostate Cancer Populations.”
From the Desk of Evan Yu: “Are More Indications for Local Therapy of Prostate Cancer on the Horizon?”
From the Desk of Evan Yu: “Sipuleucel-T…Beyond the IMPACT Trial.”
From the Desk of Evan Yu: “Prostate-specific Membrane Antigen (PSMA)-targeted Radioligand Therapies are Finally Arriving.”
From the Desk of Evan Yu: “Why Aren’t There More Systemic Therapy Trials for Patients with Muscle-invasive Urothelial Carcinoma of the Bladder?”
Just recently, we discussed neoadjuvant systemic therapy for cisplatin-ineligible patients with muscle-invasive urothelial carcinoma of the bladder.1 For those patients “unfit” for cisplatin with at least one of the following criteria: creatinine clearance <60 ml/min, grade ≥2 hearing loss, grade ≥2 neuropathy, ECOG performance status 2, and/or New York Heart Association Class III heart failure,2 there are no good options other than cystectomy alone. Yet, we know the outcomes are not ideal for these patients with cystectomy alone. Finding systemic therapies that may improve outcomes for these patients is clearly an unmet need in the field.
From the Desk of Evan Yu: “Adjuvant Therapy for Renal Cell Carcinoma?”
From the Desk of Evan Yu: “How can I keep my bladder, doc? The BCG Refractory Non-Muscle Invasive Bladder Cancer Question.”
From the Desk of Evan Yu: “PARP Inhibition for Urothelial Carcinoma…Enrichment or Combinations?”
From the Desk of Evan Yu: “Intervening on Active Surveillance of Prostate Cancer”
1-20 of 36 Next